Skip to main content

Table 3 Characterisation of EVs in saliva and tears

From: Proteomic and histopathological characterisation of sicca subjects and primary Sjögren’s syndrome patients reveals promising tear, saliva and extracellular vesicle disease biomarkers

  Mean particle size*
(nm)
Particles/mL* CD9 + EVs**
S/N ratio MFI
Tear fluid
 Pool of patients with pSS (n = 9) 255 ± 40 5.0 E+08 1.04
 Pool of patients with non-SS (n = 14) 204 ± 8 1.2 E+09 1.22
 Pool of controls (n = 10) 215 ± 9 7.1 E+08 1.20
Saliva
 Patients with pSS (n = 9) 233 ± 17 1.9 E+10 ± 0.7E+9 4.32 ± 1.19
 Patients with non-SS (n = 14) 231 ± 13 1.0 E+10 ± 1.6E+9 3.98 ± 0.57
 Controls (n = 10) 264 ± 6 7.9 E+9 ± 1.6E+9 3.22 ± 0.98
  1. *Nanoparticle tracking analysis was conducted on EV joint fractions from pooled tear fluid (n = 9 pSS, n = 14 non-SS and n = 10 controls) and whole saliva (n = 9 pSS, n = 14 non-SS and n = 10 controls), to determine mean particle size of microvesicles and exosomes (nm ± SEM), in addition to concentrations of EVs (particles/ml ± SEM)
  2. **Detection of CD9+ EVs from joint fractions of pooled tear fluid (n = 9 pSS, n = 14 non-SS and n = 10 controls), and whole saliva (n = 9 pSS, n = 14 non-SS and n = 10 controls) was performed by immunoaffinity capture using anti-CD9 coated magnetic beads followed by flow cytometry analysis. The results were reported as signal to noise (S/N) ratios of median fluorescence intensity (MFI)